Non-Myeloablative HLA-Mismatched Ex-Vivo T-Cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Siplizumab (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use
- 04 Mar 2016 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 02 Jan 2008 The expected completion date for this trial is now 1 Dec 2007.
- 02 Jan 2008 Status changed from recruiting to suspended.